A Phase 2 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Recruiting at 35 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 10th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 2, and was the 6th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Merck Sharp & Dohme LLC · Sites in Japan
Ages 1–17
Kazuya Hosokawa · Sites in Japan
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18–70
Oregon Health and Science University · Sites in United States
Ages 18+
By country, each count listing its studies:
sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 42 is close to the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc: 3 open now, 5 under way, 1 of them phase 3. Of 12 finished, 11 (92%) have results posted.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 10th largest by planned enrollment, is one of 2 that started in 2023, is one of 6 in phase 2, and was the 11th registered.
Merck & Co., Inc’s Pulmonary Arterial Hypertension studies by the year they started, since 2013.
1 of the studies testing sotatercept in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356778Kazuya HosokawaA Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, from their registry updates:
Among Merck & Co., Inc’s 17 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a subcutaneous (SC) injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
Drug: Sotatercept
SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
Also known as: MK-7962
Serum Trough Concentration (Ctrough) of Sotatercept
Ctrough was the lowest concentration of Sotatercept in serum just before the next dose. Blood samples will be collected at multiple time points to estimate the Ctrough of Sotatercept.
Time frame: Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76
Area Under the Curve at Steady State (AUCss) of Sotatercept
Blood samples will be collected at multiple time points to estimate the AUCss of Sotatercept.
Time frame: Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76
Area Under the Curve from 0 to 3 weeks (AUC0-3 weeks) of Sotatercept
Blood samples will be collected at Predose Day 1, Day 7, Day 14, and Predose Day 21 to estimate the AUC0-3 weeks of Sotatercept.
Time frame: Predose Day 1, Day 7, Day 14, and Predose Day 21
Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants with 1 or more AEs will be assessed.
Time frame: Up to 24 weeks
Percentage of Participants Who Discontinue Study Drug Due to an AE
An AE is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an adverse event. The percentage of participants who discontinued the study drug due to an AE regardless of study completion status will be assessed.
Time frame: Up to 24 weeks
Laboratory Parameter (Hematology): Concentration of Hemoglobin
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented.
Time frame: Up to 24 weeks
Laboratory Parameter (Hematology): Hematocrit
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented.
Time frame: Up to 24 weeks
Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented.
Time frame: Up to 24 weeks
Laboratory Parameter (Hematology): Reticulocyte Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented.
Time frame: Up to 24 weeks
Laboratory Parameter (Hematology): Platelet Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented.
Time frame: Up to 24 weeks
Blood Pressure (BP)
BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones).
Time frame: Up to 24 weeks
Titer of Anti-drug Antibody (ADA) to Sotatercept
ADA to Sotatercept will be assessed.
Time frame: Up to 24 weeks
Mean Change from Baseline in 6-Minute Walk Distance (6MWD) (Cohorts 1 and 2)
6MWD will be assessed using the 6-minute walk test (6MWT).
Time frame: Baseline and Week 24
Mean Change from Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)
A two-dimensional echocardiogram (ECHO) will be performed with the results interpreted by a blinded independent central review (BICR) at baseline and after 24 weeks of treatment. The change from baseline in TAPSE will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in Pulmonary Artery Systolic Pressure (PASP)
A two-dimensional ECHO will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in PASP will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in Right Ventricular Fractional Area Change (RVFAC)
A two-dimensional ECHO will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in RVFAC will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in Eccentricity Index
A two-dimensional ECHO will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in eccentricity index will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in Right Ventricular (RV) Function (Cohorts 1 and 2)
Cardiac magnetic imaging (MRI) will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in eccentricity index will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline on Cardiac Output (Cohorts 1 and 2)
Cardiac magnetic imaging (MRI) will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in cardiac output will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in Pulmonary Arterial Pressure (PAP) (Cohorts 1 and 2)
Cardiac magnetic imaging (MRI) will be performed with the results interpreted by a BICR at baseline and after 24 weeks of treatment. The change from baseline in PAP will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in Pediatric Quality of Life (PedsQL) Generic Score
PedsQL Measurement Model is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The change from baseline in the PedsQL generic core scale will be reported.
Time frame: Baseline and Week 24
Mean Change from Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP)
The change from baseline in plasma NT-proBNP levels will be reported.
Time frame: Baseline and Week 24
Percentage of Participants Who Either Improved or Maintained Their World Health Organization Functional Class (WHO FC)
The severity of an individual's PAH symptoms will be graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC will be classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC.
Time frame: Baseline and Week 24
Not enrolling at this site — choose another above.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Jan 2023 (actual). Primary completion is estimated for Sep 2028, 68 months after the start.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 68 months is above that.
Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Pulmonary Arterial Hypertension →